Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients

Journal of B.U.ON.

Volumn 13, Issue 3, 2008, Pages 349-352

  Gorumlu, G ^a   Kucukzeybek, Y ^a   Kemal Gul, M ^a   Karaca, B ^a   Cosan Terek, M ^a   Karabulut, B ^a   Sanli, U A ^a   Akman, L ^a   Ozsaran, A ^a   Dikmen, Y ^a   Uslu, Ruchan ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Chemotherapy; Ovarian carcinoma; Pegylated liposomal doxorubicin; Salvage therapy

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EPITHELIAL OVARIAN CANCER; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME;

ADENOCARCINOMA, CLEAR CELL; ADOLESCENT; ADULT; AGED; CARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; SALVAGE THERAPY; SURVIVAL RATE; YOUNG ADULT;

EID: 53849132757     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Greenlee R, Hill-Harmon M, Murray T et al. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36.
3. Ozols R. Systemic therapy for ovarian cancer: Current status and new treatments. Semin Oncol 2006; 33 (Suppl): S3-S11.
4. Latorre A, De Lena M, Catino A et al. Epithelial ovarian cancer: second and third line chemotherapy. Int J Oncol 2002; 21: 176-186.
5. Sevelda P. Second-line therapy of ovarian carcinoma. Onkologie 2000; 23: 593-596.
6. Ries LAG, Eisner MP, Kosary CL et al. (Eds): SEER Cancer Statistics Review, 1975-2000. Bethesda, National Cancer Institute, 2003.
7. West RJ, Zweig SF. Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide. Eur J Gynaecol Oncol 1997; 18: 343-348.
8. Gokhale PC, Radhakrishnan B, Husain SR et al. An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation. Br J Cancer 1996; 74: 43-48.
9. Gabizon AA. Liposomal anthracyclines. Hematol Oncol Clin North Am 1994; 8: 431-450.
10. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987-993.
11. Gordon AN, Granai CO. Rose PG et al. Phase II study of liposomal doxorubicin in platinum and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18: 3093-3100.
12. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-3322.
13. Doxil® (doxorubicin HCl liposome injection) [package insert]. Raritan, NJ: Ortho Biotech Products L.P; 2001.
14. 27 Technology Appraisal Guidance No. 45: Guidance on the use of pegylated liposomal doxorubicin hydrochloride (PLDH) for the treatment of advanced ovarian cancer. London, UK: National Institute for Clinical Excellence, 2002. Available at: http://www.nice.org.uk/ page.aspx?o=34772. Accessed July 27, 2004.
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
16. Thigpen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 1993; 71: 1559-1564.
17. Markman M, Hall J, Spitz D et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel refractory ovarian cancer. J Clin Oncol 2002; 20: 2365-2369.
18. Mutch DG, Orlando M, Goss T et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007; 25: 2811-2818.
19. Petru E, Angleitner-Boubenizek L, Reinthaller A et al. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study. Gynecol Oncol 2006; 102: 226-229.
20. Chura JC, Van Iseghem K, Downs LS Jr et al. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 2007; 107: 326-330.